JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide.
'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.'
The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families.
For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities.
Learn more about JCR, its technologies, and clinical development programs on its global website: https://jcrpharm.com/.
About the J-Brain Cargo ® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa).
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: https://jcrpharm.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
3 hours ago
- Yahoo
Earn up to 110,000 bonus miles with a new Delta SkyMiles credit card
American Express and Delta are out with all-new welcome bonus offers across three personal credit cards within the Delta SkyMiles suite: Delta SkyMiles® Gold American Express Card: Earn 80,000 bonus miles after spending $3,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum American Express Card: Earn 90,000 bonus miles after spending $4,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve American Express Card: Earn 100,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. There are also new offers on Delta business cards: Delta SkyMiles® Gold Business American Express Card: Earn 90,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum Business American Express Card: Earn 100,000 bonus miles after spending $8,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve Business American Express Card: Earn 110,000 bonus miles after spending $12,000 on eligible purchases in your first six months of card membership. With over 290 destinations across six continents and more than 200 million customers served in 2024, Delta is one of the most well-known airlines worldwide. And you could reduce much of the upfront cost of flying to one of Delta's global destinations if you're able to take advantage of these generous sign-up bonuses. It depends on how you redeem the miles, but we value Delta SkyMiles at an average of 1.18 cents each. That means 100,000 miles equals about $1,180. However, as with many airline credit cards, the exact value of your miles depends on how you use them. Since Delta uses dynamic pricing, you can see different values with each redemption. You can find plenty of value with 100,000 (give or take, depending on the welcome offer) Delta SkyMiles. This is especially true when accounting for the TakeOff 15 benefit, which provides an automatic 15% discount on eligible award flights for Delta SkyMiles cardholders. Let's take a look at some possible redemptions. You can fly from Los Angeles (LAX) to Auckland (AKL) for 38,200 miles. The cash price for the same flight is $1,341, giving you a redemption value of about 3.5 cents per mile ($1,341 / 38,200 = 0.035104). You'll still have plenty of miles left to figure out your return flight, which could mean including a stop in Australia after visiting Hobbiton (and while you're in the area). This flight from Salt Lake City (SLC) to Mexico City (MEX) will only set you back 26,300 miles. The redemption value for this flight is about 1.5 cents per mile, which is better than our average valuation. And with miles to spare, you can bring some friends or work on covering the return leg home. You don't have to get fancy with your redemptions; a short flight will do just fine if it saves you money, especially if it's a route you frequently take. Consider this example: A flight between Atlanta (ATL) and Miami (MIA) that costs 8,300 miles or $117. With 100,000 miles, you could take this flight 12 times, giving you plenty of opportunities for vacations or visiting friends and family. This particular flight has a redemption value of about 1.4 cents per mile. See which flavor — Gold, Platinum, or Reserve — of Delta SkyMiles card is the best fit for you. Consider which Delta SkyMiles business card is right for you if you run a small best Delta SkyMiles credit card for you depends on your goals and spending habits. If you only fly occasionally, maybe a few times per year, we recommend the Delta SkyMiles Gold Amex Card. This card has the lowest annual fee but still provides one of the best benefits: a free checked bag. With only a few roundtrip flights, you can offset the annual fee in saved baggage charges. If you travel a lot, a card like the Delta SkyMiles Platinum Amex Card or Delta SkyMiles Reserve Amex Card may make more sense. These cards have higher annual fees, but they also provide more benefits. For example, the Delta Reserve Amex Card offers Delta Sky Club Access (at least 15 visits each Medallion year), which could come in handy the more you find yourself in airports. Business owners can apply for the personal or business versions of the Delta SkyMiles credit cards. The business credit cards are largely the same as their personal variants, but their welcome offers require increased spending, so keep that in mind when making your decision. All the Delta SkyMiles credit cards associated with these new welcome offers have annual fees. If you want to avoid an annual fee at all costs, consider no-annual-fee credit Disclosure: The information in this article has not been reviewed or approved by any advertiser. All opinions belong solely to the Yahoo Finance and are not those of any other entity. The details on financial products, including card rates and fees, are accurate as of the publish date. All products or services are presented without warranty. Check the bank's website for the most current information. This site doesn't include all currently available offers. Credit score alone does not guarantee or imply approval for any financial product.
Yahoo
6 hours ago
- Yahoo
Florida Condo Owners Given Unique Opportunity To ‘Swap' Their Unit for House Down Payment Amid State's ‘Condo Crisis'
Florida condo owners are battling a wave of housing issues, including rising HOA fees and skyrocketing insurance costs, with little to no relief from government officials. But Phil Thompson, owner of a luxury custom homebuilder and home-renovation company, is hoping to quell the concerns of millions of condo owners in the Sunshine State with an innovative housing solution. In a swap that seems too good to be true, Thompson is offering to take condos out of the hands of frustrated Floridians and use their value as a down payment for a home under his own company, Coral Reef General Contracting in Fort Pierce. 'As far as the rules of condos, we're entertaining every offer from sellers,' Thompson tells Despite a general shift toward single-family homes in Florida, real estate agents still have a vested interest in condos, which serve a clientele who prefer their convenience, lower maintenance, or specific lifestyles. The median list price of Florida homes in May was $439,999, and condo ownership has become less affordable, particularly for those on fixed incomes in Florida, and many are looking for a way out. In what Thompson claims is a first-of-its-kind 'condo-swap' in Florida, he says he's not worried if a condo appears battered, broken, or run down. With prior experience working with New York City's high-rises, he assures Florida owners that the sky's the limit when it comes to taking in a less-than-perfect condo. 'We'll take a look from the best to the worst conditions,' says Thompson. 'We're not adverse to taking condominiums that have structural problems. I'm not concerned with that because of my structural experience from Manhattan.' Thompson sympathizes with condo owners in Florida who are scrambling to sell their property and saw an opportunity to aid those looking to level up their housing situation. 'So we're not worried about any of these problems,' he adds. 'They're all fixable. Our main concern is to get our buyers here and take the burden off our buyers' backs and make it a nice, transparent, smooth transaction for them.' Coral Reef is offering housing options on South Hutchinson Island that range from $1,500,000 to $3,000,000—depending on the property's proximity to the coastline and other amenities. Thompson says the incentive to ditch an old condo has drummed up enough marketing by itself. Despite a small loss here and there, Thompson is satisfied with the program and its impact. 'On a case-by-case basis, I may lose a few dollars on the condo, but the fact is that we bring our buyer from a negative situation into a positive situation. And it's all about word of mouth—that's how you grow, and that's how you make it in this business,' he adds. In April, both chambers of the Florida Legislature voted unanimously to pass House Bill 913, addressing endless complaints over the rising fees for condominium owners, despite pushback from Gov. Ron DeSantis. Essentially, the bill would aid condominium associations in setting up credit lines and investing funds that would contribute to necessary building repairs instead of immediately looking to owners for the money. 'You had people that were going to be forced out of their condos potentially because of legislation that had come down the pipe,' DeSantis said during a May 20 appearance in Tampa, referencing recent safety laws, as reported by NBC Miami. Condo reform laws continue after a devastating collapse of the Champlain Towers South condo in Surfside in 2021, which killed 98 people. After the incident, there was a massive effort to improve safety conditions regarding condos over 30 years of age and three stories tall. The new safety laws called for 'milestone' inspections and sought to invest in reserve funds for repairs and maintenance. Lawmakers such as state Rep. Vicki Lopez (R-Miami) have backed the bill, claiming it balances the need for structural safety with financial flexibility, particularly in the context of the rising costs of repairs and insurance for Florida condos, as reported by the Florida Phoenix. 'This incredible bill addressing the condominium crisis we have all heard about for the last year gives a lot of financial relief,' Lopez says. The bill also introduces electronic voting, making it easier for condo owners to participate in decisions, which could be DeSantis' main point of objection. Despite some reservations, Florida lawmakers are confident that the governor will sign the bill, as he's spoken about the condo issue on several occasions in the past couple of months. 'We have this condo issue, that legislation that caused these crushing assessments,' DeSantis said during a press conference in Fruitland Park. 'We know people need relief from that. We've got to do it. The Senate's got a great product that can do it.' HB 913 has been sent to the governor's desk for his signature. Once signed, the bill goes into effect on July 1. 'Captain America' Star Chris Evans Puts L.A. Home on the Market for $7 Million as He Quits California To Move Back to East Coast Inside NBC 'Nightly News' Host Lester Holt's Property Portfolio as He Steps Down After a Decade Billy Joel Relists 14-Acre Main Portion of His Long Island Estate for $29.9 Million
